Home > Research > Publications & Outputs > Uptake of novel statistical methods for early p...

Links

Text available via DOI:

View graph of relations

Uptake of novel statistical methods for early phase clinical studies in the UK public sector

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Uptake of novel statistical methods for early phase clinical studies in the UK public sector. / Jaki, Thomas.

In: Clinical Trials, Vol. 10, No. 2, 04.2013, p. 344-346.

Research output: Contribution to journalJournal articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{7a63d8c3c05e4e09b781b706d18366a7,
title = "Uptake of novel statistical methods for early phase clinical studies in the UK public sector",
abstract = "Background In recent years, the success rate of confirmatory studies has been poor resulting in more emphasis on the conduct of exploratory studies. As one possibility to improve decision-making during the early stages of development, adaptive and Bayesian methods have been recommended.Purpose To investigate the current practice in designing early-phase studies in UK public sector research institutions and the use of adaptive and Bayesian methods in particular and to determine factors that hinder the penetration of methodological advances into practice.Methods A questionnaire was sent to all UK clinical trials units (CTUs) to gauge their involvement in early-phase studies and to learn about the designs used in these studies. Follow-up visits to units conducting early-phase studies with round-table discussions around the methods used and the obstacles faced when using adaptive methods were undertaken.Results More than half of the CTUs are involved in early-phase studies, but conservatism in the methods used in these studies is present. Reasons for novel methodology not being used include a lack of expertise, incompatible funding and unit structure, and a lack of software.Limitations Information is collected from UK CTUs, which undertake a large portion (but not all) publicly funded trials.Conclusions The use of adaptive and Bayesian methods for early-phase clinical studies in the UK public sector is at present limited. Various different initiatives aim to support and facilitate the use of these methods, however, so that an increased use of these methods can be anticipated in the future.",
author = "Thomas Jaki",
year = "2013",
month = apr,
doi = "10.1177/1740774512474375",
language = "English",
volume = "10",
pages = "344--346",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Uptake of novel statistical methods for early phase clinical studies in the UK public sector

AU - Jaki, Thomas

PY - 2013/4

Y1 - 2013/4

N2 - Background In recent years, the success rate of confirmatory studies has been poor resulting in more emphasis on the conduct of exploratory studies. As one possibility to improve decision-making during the early stages of development, adaptive and Bayesian methods have been recommended.Purpose To investigate the current practice in designing early-phase studies in UK public sector research institutions and the use of adaptive and Bayesian methods in particular and to determine factors that hinder the penetration of methodological advances into practice.Methods A questionnaire was sent to all UK clinical trials units (CTUs) to gauge their involvement in early-phase studies and to learn about the designs used in these studies. Follow-up visits to units conducting early-phase studies with round-table discussions around the methods used and the obstacles faced when using adaptive methods were undertaken.Results More than half of the CTUs are involved in early-phase studies, but conservatism in the methods used in these studies is present. Reasons for novel methodology not being used include a lack of expertise, incompatible funding and unit structure, and a lack of software.Limitations Information is collected from UK CTUs, which undertake a large portion (but not all) publicly funded trials.Conclusions The use of adaptive and Bayesian methods for early-phase clinical studies in the UK public sector is at present limited. Various different initiatives aim to support and facilitate the use of these methods, however, so that an increased use of these methods can be anticipated in the future.

AB - Background In recent years, the success rate of confirmatory studies has been poor resulting in more emphasis on the conduct of exploratory studies. As one possibility to improve decision-making during the early stages of development, adaptive and Bayesian methods have been recommended.Purpose To investigate the current practice in designing early-phase studies in UK public sector research institutions and the use of adaptive and Bayesian methods in particular and to determine factors that hinder the penetration of methodological advances into practice.Methods A questionnaire was sent to all UK clinical trials units (CTUs) to gauge their involvement in early-phase studies and to learn about the designs used in these studies. Follow-up visits to units conducting early-phase studies with round-table discussions around the methods used and the obstacles faced when using adaptive methods were undertaken.Results More than half of the CTUs are involved in early-phase studies, but conservatism in the methods used in these studies is present. Reasons for novel methodology not being used include a lack of expertise, incompatible funding and unit structure, and a lack of software.Limitations Information is collected from UK CTUs, which undertake a large portion (but not all) publicly funded trials.Conclusions The use of adaptive and Bayesian methods for early-phase clinical studies in the UK public sector is at present limited. Various different initiatives aim to support and facilitate the use of these methods, however, so that an increased use of these methods can be anticipated in the future.

U2 - 10.1177/1740774512474375

DO - 10.1177/1740774512474375

M3 - Journal article

VL - 10

SP - 344

EP - 346

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 2

ER -